sb 203580 has been researched along with Kidney Tubular Transport, Inborn Error in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Endo, Y; Kasamatsu, A; Kita, A; Koike, K; Nakashima, D; Saito, T; Sawai, Y; Shiiba, M; Takiguchi, Y; Tanzawa, H; Toeda, Y; Uzawa, K | 1 |
1 other study(ies) available for sb 203580 and Kidney Tubular Transport, Inborn Error
Article | Year |
---|---|
Growth suppression of human oral cancer cells by candidate agents for cetuximab-side effects.
Topics: Animals; Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Therapy, Combination; ErbB Receptors; Exanthema; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Growth Inhibitors; HEK293 Cells; Humans; Hypercalciuria; Imidazoles; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Nephrocalcinosis; Pyridines; Renal Tubular Transport, Inborn Errors; Transcriptome; Xenograft Model Antitumor Assays | 2019 |